icon

It's not every day that a company set to launch an innovative and potentially groundbreaking new product line in a billion dollar sector trades below the radar for too long, but that might be exactly the case with ChromaDex Corp (CDXC) right now.

By combining science and nature, ChromaDex has harnes...

Read more

CytRx Corporation, a company with an oncology pipeline that is bubbling with potential, made radars last Friday when over thirteen million shares traded with no news being released in conjunction with the volume spike. The daily trading average of CYTR is under 800,000, so Friday's significant actio...

Read more

It didn't take long for ChromaDex to issue an announcement that warrants a quick follow-up to my earlier write-up about the company. Chromadex, which looks to be in the beginning stages of building an empire on a product created after its science harnessed the natural powers of the blueberry, just u...

Read more

Shares of SIGA Technologies could be set to rebound nicely over the next few weeks.

The company announced on Monday evening that the protest filed against the awarding of the BARDA contract that would have SIGA supply the nation's biodefense stockpile will millions of courses of its smallpox antivira...

Read more

It's been a nice couple of weeks for Cel-Sci's Multikine partners.

Late last week Orient Europharma kicked off its portion of the Multikine Phase III trial in Taiwan, and on Monday morning it was announced that Teva has commenced the Israeli portion of the trial as well.
According to a Monday press re...

Read more

Early last week Generex Biotechnology Corp. issued a press release that outlined the current status of the Oral-lyn development program. Oral-lyn is the company's developmental insulin spray that delivers insulin buccally through the inner lining of the cheek.

This flagship product had been the key t...

Read more

Positive developments from Epicept Corporation over the past six months have made this a nice rebound story, although the share price hasn't responded just yet, and if the pipeline continues to advance at the current pace while Ceplene catches on in the markets in which its sold, then the future cou...

Read more

Keep an eye on the following stocks this week...

DNDN: Dendreon will be a stock to watch this week.

A large part of this company being able to meet year-end sales guidance for the prostate cancer immunotherapy, Provenge, has to do with The FDA approving a new manufacturing facility in Los Angeles, Cal...

Read more

Generex Drops

Posted by Posted by VFC on Jun 25, 2011

GNBT: Shares of Generex (GNBT) were pummelled on Friday, dropping 25% on volume more than four times the daily average. Although shareholders finally approved a reverse split earlier this month, investors remain skeptical about the short to mid term potential of the company after it was also announc...

Read more

It's been a rough, rough year for Labopharm (DDSS) and its shareholders, as bad news has been compounded by more bad news, which leaves the current share price at a very unimpressive sixteen cents.

To follow up on all the discouraging news, the company announced that its joint venture with Italy's Gr...

Read more

CVM: Cel-Sci Corp. announced on Thursday that its partner in Taiwan, Orient Europharma, has completed the necessary final steps before patient enrollment into the Multikine Phase III trial can commence.

According to a CVM press release, the Multikine that will be used for the Taiwan portion of the tr...

Read more

Here's one you don't see every day.

Cel-Sci Corp. is currently conducting a world-wide Phase III clinical trial for its lead product, Multikine, an 'off the shelf' cancer immunotherapy that the company predicts will become a blockbuster first-line treatment for head and neck cancer.

Looking to see Mul...

Read more

Last week we discussed the multiple setbacks experienced by SIGA Technologies in landing a BARDA contract to supply the nation's biodefense stockpiles with ST-246, a vaccine for smallpox. The usual culprit in these setbacks has been Siga-competitor Chimerix, Inc., who on multiple occasions has filed...

Read more

Already labeled as a stock to watch for its year-long price increase and powerful pipeline potential, shares of Immunocellular broke through the two dollar mark again on Tuesday after announcing that the company had been granted a key patent to regarding its cancer-fighting technology.

The patent, nu...

Read more

Last week Generex Biotechnology Corp. issued an update on the status of its Oral-lyn program.

Previous estimations had investors believing that results from the Phase III trial would be due during the earlier parts of 2011, but those results never materialized. Investors, in turn, started to become ...

Read more

Other issues were discussed at this year's edition of the Epicept meeting of the shareholders, according to an early-morning press release on Monday, but the pronounced theme for the near-term future of this company is 'Reverse Split'.

The meeting was adjourned until June 27, 2011, at 10:00 a.m. EDT,...

Read more

SIGA: Fresh off a week where Siga Technologies received yet another set back in the final awarding of a BARDA contract to supply a smallpox antiviral to the nation's biodefense stockpiles, SIGA will be one to keep a close eye on during the coming days.

Generally, it's Siga's antiviral competitor, Chi...

Read more

The heavy lifting is done for Generex management, having achieved the goal of receiving shareholder approval to conduct a reverse stock split. With the vote now down in the history books, it's about that time to start looking to the future.

A big part of that future revolves around the spin-off of Ge...

Read more

ACTC: The historic trials that launched Advanced Cell Technology (ACT) from a little-known, sub-dime OTCBB company into the main stream of embryonic stem cell treatment are underway. ACT announced on Thursday that the first patients were enrolled in the Stargardt's Macular Dystrophy (SMD) and Dry Ag...

Read more

Shares of Celsius Holdings have been deflated to the twenty to thirty cent level for the better part of 2011, and volume has grown minuscule as the year has progressed. Only three days in June has CELH experienced more trading volume than 10,000, and on June 8th, a whopping 100 shares traded hands.

...

Read more

CVM: Are You Hungary For News?

Posted by Posted by VFC on Jun 15, 2011

Cel-Sci's global Phase III trialfor its experimental head and neck cancer vaccine, Multikine, has commenced in Hungary. According to a press release issued on Monday, the trial will soon start enrolling patients at the National Institute of Oncology in Budapest, Hungary.

Cel-Sci has issued numerous P...

Read more

Cancer treatment is an ever-evolving business, with many potential breakthroughs and blockbusters being developed by small companies on any given day. Shareholders who are hoping to tag along as part of either an historical FDA approval or an historical share price run are always on the lookout for ...

Read more

It was an historic day for the future of cancer treatment when the FDA approved Dendreon's (DNDN) Provenge for the treatment of prostate cancer just over one year ago. It opened the doors to a new age in the treatment of cancer and shareholders delighted alongside victims of prostate cancer patients...

Read more

Already a stock to watch due to a solid pipeline of cancer treating products, CytRx Corporation (CYTR) issued a Monday morning press release announcing positive preliminary results from its ongoing ENABLE Phase 2 proof-of-concept trial for bafetinib in the treatment of relapsed or refractory B-cell ...

Read more

CYTR: Keep an eye on shares of CytRx. The stock was down by another five percent on Friday, but it's a stock that might not be held down for too long as the company has a solid pipeline of cancer-fighting products that would enter some pretty lucrative markets, if approved.

CytRx has been successful ...

Read more

For the better part of the year so far, as Capstone Turbine more than doubled in value, The Motley Fool has been playing the short side of the coverage, emphasizing the modest profit margins of the company's microturbines. That negative coverage may be changing course as a luke-warm review of Capsto...

Read more

CytRx (CYTR) Corporation, with a rapidly advancing pipeline and money in the bank, may be skimming below the radar for investors searching for an undervalued company that might be gearing up to make a big splash in the cancer treatment sector.

Companies with products that are not yet beyond Phase II,...

Read more

The DOW may be sliding to the sub 12,000 mark again, and the economy may be taking a turn for the worse again, but none of that will put a damper on the mood at Generex Headquarters, where news that shareholders have finally agreed to a reverse split is undoubtedly causing some long-suppressed elati...

Read more

As shares of Capstone Turbine dipped back into buy territory, some positive analyst coverage and another notable sales order instilled some renewed vigor into the stock.

CPST closed Monday at $1.65, up only a nickel from its previous close, but early-day trading saw the stock hit $1.73 before the pul...

Read more

Late last year, when the management team at Generex was looking to entice shareholders to vote for a reverse split, a deal with Global Medical Direct (GMD) was announced, in which Generex would acquire 51% of the nationwide Durable Medical Equipment and Pharmaceutical provider - which specializes in...

Read more

Epicept Corp. announced during the early hours on Tuesday that it had received a positive panel decision for continued listing on the NASDAQ board.

The positive decision will keep EPCT able to trade on the Nasdaq until September, at which time consideration will be given to the listing guidelines, wh...

Read more

It turns out that Friday's volume and price spike for shares of CTSO were in anticipation of Monday's release of the 'Letter to Shareholders', which - upon its release - sparked an additional spike to twenty three cents, before falling back down to close at nineteen cents.

The shareholder letter anno...

Read more

CTSO: A 10% price move on Friday will have investors interested this coming week.

News of secondary endpoints for the European CytoSorb trial will be key in determining the market potential of the CytoSorb, once commercialized, and the prospects of the company landing a deep-pocketed partner to help ...

Read more

In an apparent bid to streamline the news events and developments leading into the vote for a reverse split of the GNBT stock, Generex has the printing press working overtime this week.

On the heels of announcing a licensing deal with Amarantus BioSciences for the buccal spray technology behind Rapid...

Read more

Titan: Still On The Watch List

Posted by Posted by VFC on Jun 03, 2011

TTNP: Can we discuss this stock enough these days?

With Probuphine results just weeks away - if that, and with the prospects of Titan landing a big partner growing in probability every day, TTNP continues to be an intriguing pick as the stock finally re-took the $2 mark and remained there for a few d...

Read more

Could next week be the week that investors receive the much-anticipated follow-up news to the CE Mark Approval for CytoSorb earlier this year?

Shares of CTSO recently fell below the twenty cent mark, and volume has become relatively flat in the meantime.

The last couple of hours of trading on Friday w...

Read more

It's been about, what, two years now since the FDA approved BioDelivery's treatment for cancer pain, ONSOLIS?

And two years later the company is still awaiting a final decision from the FDA regarding the REMS issue which has limited the market potential of the company's flagship product.

According to ...

Read more

ONTY: Oncothyreon shares have been well on the fly of late, setting a new 52-week high last week of $6.50.
Stimuvax trials are winding down right now, with results probable to start leaking out towards the end of the year, and if the trial for non-small cell lung cancer proves to have been a success...

Read more

AVNR: It was a wild ride for AVNR last week, with volatility and volume dragging shares down early in the week before rebounding to a close of $4.67.
Is the up-volume a sign that the large short position is in the process of being covered?

Possible, but there also a couple of other concerns surroundin...

Read more

It was off to the races for shares of Multicell Technologies on Tuesday when the company announced that it had been granted a patent from the US Patent and Trademark Office relating to the isolation and use of human liver stem cells to treat liver disease.

At the end of the trading day, MCET had gai...

Read more

Epicept Announces Financing

Posted by Posted by VFC on Jun 01, 2011

The potential of Epicept has been moving along at a more solid pace over the past six months than in the couple of years before that when it looked as if the company might have been on the brink of becoming a has-been or never-was.

Although the latest quarterly results showed that Ceplene has yet to ...

Read more

Shares of Generex remained relatively unchanged after the company announced on Tuesday morning that it entered into a licensing agreement with Amarantus BioSciences, Inc. for the buccal drug delivery technology behind Generex's RapidMist spray.

Generex will receive a non-refundable fee of $10 million...

Read more

CytRx (CYTR) Corporation, with a rapidly advancing pipeline and money in the bank, may be skimming below the radar for investors searching for an undervalued company that might be gearing up to make a big splash in the cancer treatment sector.

Companies with products that are not yet beyond Phase II,...

Read more